Screener
Zevra Therapeutics, Inc. ZVRA Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Zevra Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
FAQ
- What is Zevra Therapeutics, Inc.'s debt-to-equity?
- Zevra Therapeutics, Inc. (ZVRA) reported debt-to-equity of 0× in Q2 2026.
- How has Zevra Therapeutics, Inc.'s debt-to-equity changed year-over-year?
- Zevra Therapeutics, Inc.'s debt-to-equity decreased by 98.7% year-over-year, from 0.5× to 0×.
- What is the long-term trend for Zevra Therapeutics, Inc.'s debt-to-equity?
- Over 4 years (2021 to 2025), Zevra Therapeutics, Inc.'s debt-to-equity has grown at a 125.5% compound annual growth rate (CAGR), from 0× to 0.4×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Zevra Therapeutics, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude